This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (ALC)

Tipranks - Tipranks - Sat Jun 13, 6:36AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (ALC) with bullish sentiments.

Introducing TipRanks MCP for Agents

Evommune, Inc. (EVMN)

In a report released today, Judah Frommer from Morgan Stanley maintained a Buy rating on Evommune, Inc., with a price target of $55.00. The company’s shares closed last Thursday at $20.69.

According to TipRanks.com, Frommer is a 1-star analyst with an average return of -0.2% and a 51.6% success rate. Frommer covers the Healthcare sector, focusing on stocks such as Lakefront Biotherapeutics, 4D Molecular Therapeutics, and Bicara Therapeutics Inc. ;'>

Currently, the analyst consensus on Evommune, Inc. is a Strong Buy with an average price target of $52.00, representing a 156.0% upside. In a report issued on June 10, William Blair also maintained a Buy rating on the stock.

See the top stocks recommended by analysts >>

Immunome (IMNM)

J.P. Morgan analyst Brian Cheng reiterated a Buy rating on Immunome today and set a price target of $39.00. The company’s shares closed last Thursday at $18.36.

According to TipRanks.com, Cheng is a 4-star analyst with an average return of 5.0% and a 50.0% success rate. Cheng covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Kyverna Therapeutics, Inc., and Odyssey Therapeutics, Inc. ;'>

Immunome has an analyst consensus of Strong Buy, with a price target consensus of $35.77, representing a 97.8% upside. In a report issued on May 28, Barclays also initiated coverage with a Buy rating on the stock with a $36.00 price target.

Alcon (ALC)

In a report released today, Brett Fishbin from KeyBanc reiterated a Buy rating on Alcon, with a price target of $88.00. The company’s shares closed last Thursday at $66.51.

According to TipRanks.com, Fishbin ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.3% and a 37.1% success rate. Fishbin covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Solventum Corporation, and Lemaitre Vascular. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alcon with a $88.36 average price target, representing a 32.6% upside. In a report released yesterday, Citi also maintained a Buy rating on the stock with a $103.00 price target.

Read More on EVMN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).